Beam Therapeutics Inc. saw its stock price soar 5.23% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.
The surge appears to be driven by positive analyst actions, with Clear Street reaffirming its Buy rating on the stock and setting a price target of $37.00, while Wedbush raised its price target on Beam Therapeutics from $57 to $65.
These analyst upgrades and reaffirmations have likely boosted investor confidence in the company's prospects, contributing to the strong buying activity during the trading session.